Market Place
Sourcing Support
Akero Presents Efruxifermin Data At AASLD The Liver Meeting 2024
21 Oct 2024 //
GLOBENEWSWIRE
Akero Therapeutics To Present At H.C. Wainwright MASH Conference
30 Sep 2024 //
GLOBENEWSWIRE
Akero Announces First Patient Dosed In SYNCHRONY Study
09 Sep 2024 //
GLOBENEWSWIRE
Akero Therapeutics To Present At Morgan Stanley Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Akero Therapeutics Reports Q2 2024 Results And Business Update
09 Aug 2024 //
GLOBENEWSWIRE
Akero Therapeutics Announces Initiation of Ph 3 SYNCHRONY Outcomes
11 Jun 2024 //
GLOBENEWSWIRE
Akero Therapeutics Presents Poster and Oral Presentation on EFX at EASL Congress
07 Jun 2024 //
GLOBENEWSWIRE
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Akero Therapeutics Q1 2024 Financials, Business Update
10 May 2024 //
GLOBENEWSWIRE
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
08 May 2024 //
GLOBENEWSWIRE
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
30 Apr 2024 //
GLOBENEWSWIRE
Akero Therapeutics Announces Closing of Public Offering of Common Stock
08 Mar 2024 //
GLOBENEWSWIRE
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study
07 Mar 2024 //
GLOBENEWSWIRE
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
05 Mar 2024 //
GLOBENEWSWIRE
Akero Bounces Back in MASH, Posts Positive Mid-Stage Fibrosis Data
05 Mar 2024 //
BIOSPACE
Akero Therapeutics Reports Improvements at Week 96 in Phase 2b HARMONY Study
04 Mar 2024 //
GLOBENEWSWIRE
Akero Therapeutics Announces Proposed Public Offering of Common Stock
04 Mar 2024 //
GLOBENEWSWIRE
Akero Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Akero to Present Topline Week 96 Results from Phase 2b HARMONY Study
29 Feb 2024 //
GLOBENEWSWIRE
Akero Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Akero Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
18 Dec 2023 //
GLOBENEWSWIRE
Akero Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX
10 Nov 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
08 Nov 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Conference
17 Oct 2023 //
GLOBENEWSWIRE
Akero`s NASH miss drags a few peers down, spurring deja vu
11 Oct 2023 //
FIERCE BIOTECH
Akero Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study
10 Oct 2023 //
PRESS RELEASE
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results
04 Oct 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
31 Aug 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
28 Aug 2023 //
GLOBENEWSWIRE
Akero Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Looking At Akero Therapeutics`s Recent Unusual Options Activity
27 Jun 2023 //
BENZINGA
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study
23 Jun 2023 //
GLOBENEWSWIRE
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
21 Jun 2023 //
FIERCE BIOTECH
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety
05 Jun 2023 //
PRESS RELEASE
Akero to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial
01 Jun 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
How Much Upside is Left in Akero? Wall Street Analysts Think 29.22%
23 May 2023 //
NASDAQ
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering
16 May 2023 //
GLOBENEWSWIRE
Akero Therapeutics Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
Can Akero Climb 42.57% to Reach the Level Wall Street Analysts Expect?
18 Apr 2023 //
NASDAQ
Akero Therapeutics Announces SYNCHRONY Phase 3 Program for Efruxifermin in NASH
29 Mar 2023 //
PRESS RELEASE
Akero Announces Positive SYNCHRONY Phase 3 Program for Efruxifermin
29 Mar 2023 //
GLOBENEWSWIRE
89bio hits primary goals in midphase NASH trial, plots phase 3
23 Mar 2023 //
FIERCE BIOTECH
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
17 Mar 2023 //
GLOBENEWSWIRE
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President
10 Jan 2023 //
GLOBENEWSWIRE
Akero Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Akero Therapeutics Reaches Analyst Target Price
30 Dec 2022 //
NASDQ
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study
21 Dec 2022 //
GLOBENEWSWIRE
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
08 Dec 2022 //
GLOBENEWSWIRE
Akero Therapeutics: What Is Making The Stock Tick
23 Nov 2022 //
SEEKING ALPHA
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
10 Nov 2022 //
GLOBENEWSWIRE
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX
07 Nov 2022 //
GLOBENEWSWIRE
Akero Therapeutics Reports 3Q FYR and Provides Business Update
04 Nov 2022 //
GLOBENEWSWIRE
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock
19 Sep 2022 //
GLOBENEWSWIRE
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
14 Sep 2022 //
GLOBENEWSWIRE
With positive PhII NASH data in tow, Akero opens $175M public offering
14 Sep 2022 //
ENPTS
Akero rockets as NASH drug hits targets in phase 2b trial
14 Sep 2022 //
PHARMAPHORUM
In Akero`s Ph2b HARMONY Study, Both 50mg & 28mg EFX Doses Achieved Significance
13 Sep 2022 //
PRESS RELEASE
